phrykt

BioRestorative Therapies, Inc. (BRTX): who owns it and who trades it

As of Nov 16, 2026, no open-market insider purchases or sales of BRTX were reported in the last 12 months. 1 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Insider trades

No BRTX insider reported an open-market purchase or sale in the last 12 months.

Purchases, 12 months
$0
0 trades, 0 people
Sales, 12 months
$0
0 trades, 0 people
Sales under a 10b5-1 plan
–
Share of sale value
Latest trade
–
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

BRTX short interest

36,404 BRTX shares are sold short. Over the last 12 reports the number of shares short went down 90%.

As of Oct 30, 2026, 36,404 BRTX shares were sold short, up 146.3% from the report before. At the average daily volume of 38,359 shares, buying them all back would take about 1.0 trading days (days to cover).

Shares short, % of all shares

0.05%May 15Sep 3029.7%

Days to cover

1.0May 15Oct 302.9

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 202636,404–+146%38,3591.0
Oct 15, 202614,778–+12%41,2201.0
Sep 30, 202613,1520.05%+14%33,0711.0
Sep 15, 202611,5860.05%-69%40,5531.0
Aug 31, 202637,6410.15%-62%175,5791.0
Aug 14, 202699,6870.39%-79%298,4771.0
Jul 31, 2026463,9661.82%-40%430,0281.1
Jul 15, 2026772,0083.03%-30%294,2952.6
Jun 30, 20261.11M4.34%-14%582,7681.9
Jun 15, 20261.28M5.03%-81%1.90M1.0
May 29, 20266.59M25.86%+1687%65.16M1.0
May 15, 2026368,6651.45%-43%1.05M1.0

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

BioRestorative Therapies company events

BioRestorative Therapies filed 14 reports on Form 8-K in the last 12 months, 10 of them about an important change (leadership, listing, auditor). The latest was on Oct 9, 2026.

  1. Oct 9, 2026LeadershipThe Board of Directors of BioRestorative Therapies, Inc. appointed Donald J. Currie as a Class I director of the Company, effective immediately, to fill the vacancy created by the previously reported resignation of Katharyn Field as a director effective August 31, 2026. Filing
  2. Sep 11, 2026LeadershipBioRestorative Therapies, Inc. received a notice of resignation from Mr. Silva from his employment with the Company, including as the Company’s Vice President of Research and Development, and from each other position (if any) he held as an officer of the Company, effective immediately. Filing
  3. Sep 10, 2026AuditorAmended an earlier report. Of the Original Form 8-K regarding (i) reportable events (within the meaning of Item 304(a)(1)(v) of Regulation S-K) discussions with CBIZ CPAs P.C., (ii) an investigation being performed by the Company’s audit committee, and (iii) the scope of the Company’s engagement of Bush & Associates CPA. No… Filing
  4. Sep 2, 2026SharesChanged the rights of its shareholders. Filing
  5. Sep 2, 2026AuditorChanges in Registrant’s Certifying Accountant. Filing
  6. Aug 25, 2026ListingBioRestorative Therapies, Inc. received a delinquency notification letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC indicating that, as a result of the Company’s inability to timely file its Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2026… Filing
  7. Aug 14, 2026AnnouncementBioRestorative Therapies, Inc. suspended, effective immediately, all orders and shipments of its biocosmeceutical product lines, consisting of its ExoCR products and its BioX products, pending a business review and regulatory assessment. Filing
  8. Jul 16, 2026LeadershipThe Company entered into amendments to (i) the Employment Agreement, dated as of May 27, 2026, between the Company and Lance Alstodt, then the Company’s President, Chief Executive Officer and Chairman of the Board, (ii) the Employment Agreement, dated as of May 27, 2026, between the Company and… Filing
  9. Jun 12, 2026LeadershipBioRestorative Therapies, Inc. and Francisco Silva, its Vice President, Research and Development, entered into an employment agreement which provides for a term ending on June 10, 2029. Filing
  10. Jun 12, 2026LeadershipHereof with regard to the resignation of certain directors of the Company pursuant to the Revolving Loan Agreement and the appointment of certain new directors designated by the Lender. Filing
  11. May 29, 2026LeadershipBioRestorative Therapies, Inc. and Lance Alstodt, its President, Chief Executive Officer and Chairman of the Board, entered into an employment agreement which provides for a term ending on May 27, 2029. Filing
  12. May 1, 2026LeadershipThe Compensation Committee of the Board of Directors of BioRestorative Therapies, Inc. approved cash bonuses for the Company’s executive officers for the year ended December 31, 2025, as set forth below in the updated Summary Compensation Table. Filing
  13. Apr 23, 2026AnnouncementShared information with investors. Filing
  14. Feb 17, 2026AgreementBioRestorative Therapies, Inc. commenced a public offering of an aggregate of (a) 12,560,715 units, consisting of (i) 12,560,715 shares of the Company’s common stock, par value $0.0001 per share and (ii) five-year warrants to purchase up to 12,560,715 shares of Common Stock, at an offering price of… Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

BioRestorative Therapies financials

Famous investors that hold BRTX

1 of the 50 well-known investors we track reported holding BRTX in their latest 13F filing. The largest position is Ken Griffin's, worth $72.1K.

FundQuarterSharesValueOf portfolioChange
Ken Griffin · Citadel AdvisorsQ3 202630,951$72.1K0.0%New

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

Questions about BioRestorative Therapies, Inc. (BRTX) stock

Are BRTX insiders buying or selling?

No BRTX insider reported an open-market purchase or sale on Form 4 in the last 12 months. Share awards, option exercises and gifts are not counted.

What is the short interest in BRTX?

As of Oct 30, 2026, 36,404 BRTX shares were sold short, up 146.3% from the report before. At the average daily volume of 38,359 shares, buying them all back would take about 1.0 trading days (days to cover). See the history.

Which famous investors hold BRTX?

1 of the 50 well-known investors we track reported BRTX in their latest 13F filing, including Ken Griffin. The largest position is worth $72.1K. See all holders.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.